Biomarkers: Hopes and challenges in the path from discovery to clinical practice

Translational Research

Volumn 159, Issue 4, 2012, Pages 197-204

  Frangogiannis, Nikolaos G ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 15; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE MB; CYSTATIN C; FATTY ACID BINDING PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN A1C; INTERLEUKIN 18; ISCHEMIA MODIFIED ALBUMIN; KIDNEY INJURY MOLECULE 1; LACTATE DEHYDROGENASE; MYELOPEROXIDASE; PENTRAXIN; TROPONIN I; TROPONIN T; TUMOR MARKER;

ACUTE CORONARY SYNDROME; ACUTE GRAFT REJECTION; ACUTE HEART INFARCTION; ACUTE LUNG INJURY; BIOPSY; CANCER CELL; CANCER SCREENING; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL PRACTICE; DIABETES MELLITUS; DNA MODIFICATION; DOCUMENTATION; DYSPNEA; ENDOSCOPY; ENTERITIS; GENOMICS; HEART FAILURE; HEART INJURY; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOTHESIS; MASS SPECTROMETRY; METABOLOMICS; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; PUBLICATION; RESPIRATORY DISTRESS SYNDROME; REVIEW; RISK ASSESSMENT; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDATION STUDY;

EID: 84858419467     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.01.023     Document Type: Note

References (46)

1. N. Rifai, M.A. Gillette, and S.A. Carr Protein biomarker discovery and validation: the long and uncertain path to clinical utility Nat Biotechnol 24 2006 971 983
2. Biomarkers definitions working group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
3. R.S. Vasan Biomarkers of cardiovascular disease: molecular basis and practical considerations Circulation 113 2006 2335 2362
4. J. Laurence No more boring science, no more waste in clinical trials Transl Res 153 2009 1 3
5. P.M. Bossuyt The thin line between hope and hype in biomarker research JAMA 305 2011 2229 2230
6. S. Gutman, and L.G. Kessler The US Food and Drug Administration perspective on cancer biomarker development Nat Rev Cancer 6 2006 565 571
7. D.A. Morrow, and J.A. de Lemos Benchmarks for the assessment of novel cardiovascular biomarkers Circulation 115 2007 949 952
8. A.G. Paulovich, J.R. Whiteaker, A.N. Hoofnagle, and P. Wang The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline Proteomics Clin Appl 2 2008 1386 1402
9. R.E. Gerszten, A. Asnani, and S.A. Carr Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics Circ Res 109 2011 463 474
10. M.G. Tektonidou, and M.M. Ward Validation of new biomarkers in systemic autoimmune diseases Nat Rev Rheumatol 7 2011 708 717
11. L.D. Fiore, and L.W. D'Avolio Detours on the road to personalized medicine: barriers to biomarker validation and implementation JAMA 306 2011 1914 1915
12. J.P. Ioannidis, and O.A. Panagiotou Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses JAMA 305 2011 2200 2210
13. A.S. Maisel, P. Krishnaswamy, R.M. Nowak, J. McCord, J.E. Hollander, and P. Duc Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N Engl J Med 347 2002 161 167
14. A. Maisel, C. Mueller, K. Adams Jr., S.D. Anker, N. Aspromonte, and J.G. Cleland State of the art: using natriuretic peptide levels in clinical practice Eur J Heart Fail 10 2008 824 839
15. M. O'Donoghue, and E. Braunwald Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol 7 2010 13 20
16. G.D. Lewis, R. Wei, E. Liu, E. Yang, X. Shi, and M. Martinovic Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury J Clin Invest 118 2008 3503 3512
17. G.D. Lewis, A. Asnani, and R.E. Gerszten Application of metabolomics to cardiovascular biomarker and pathway discovery J Am Coll Cardiol 52 2008 117 123
18. D.W. Kehl, N. Iqbal, A. Fard, B.A. Kipper, A. De La Parra Landa, and A.S. Maisel Biomarkers in acute myocardial injury Transl Res 159 2012 252 264
19. C.R. Roe Diagnosis of myocardial infarction by serum isoenzyme analysis Ann Clin Lab Sci 7 1977 201 209
20. F.S. Apple, R.L. Jesse, L.K. Newby, A.H. Wu, and R.H. Christenson National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes Circulation 115 2007 e352 e355
21. W. Hochholzer, D.A. Morrow, and R.P. Giugliano Novel biomarkers in cardiovascular disease: update 2010 Am Heart J 160 2010 583 594
22. S. Gupta, and J.A. de Lemos Use and misuse of cardiac troponins in clinical practice Prog Cardiovasc Dis 50 2007 151 165
23. B.M. Scirica Acute coronary syndrome: emerging tools for diagnosis and risk assessment J Am Coll Cardiol 55 2010 1403 1415
24. M.S. Sabatine, D.A. Morrow, J.A. de Lemos, P. Jarolim, and E. Braunwald Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35 Eur Heart J 30 2009 162 169
25. R.T. Dadu, V. Nambi, and C.M. Ballantyne Developing and assessing cardiovascular biomarkers Transl Res 159 2012 265 276
26. P.M. Ridker Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity Nutr Rev 65 12 Pt 2 2007 S253 S259
27. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
28. M.A. Hlatky Expanding the orbit of primary prevention-moving beyond JUPITER N Engl J Med 359 2008 2280 2282
29. V. Vaccarino, J.D. Bremner, and M.E. Kelley JUPITER: a few words of caution Circ Cardiovasc Qual Outcomes 2 2009 286 288
30. C.A. Labarrere, and B.R. Jaeger Biomarkers of heart transplant rejection: the good, the bad, and the ugly! Transl Res 159 2012 238 251
31. M.X. Pham, J.J. Teuteberg, A.G. Kfoury, R.C. Starling, M.C. Deng, and T.P. Cappola Gene-expression profiling for rejection surveillance after cardiac transplantation N Engl J Med 362 2010 1890 1900
32. C.A. Labarrere, J.B. Lee, D.R. Nelson, M. Al-Hassani, S.J. Miller, and D.E. Pitts C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study Lancet 360 2002 1462 1467
33. L. Hartwell, D. Mankoff, A. Paulovich, S. Ramsey, and E. Swisher Cancer biomarkers: a systems approach Nat Biotechnol 24 2006 905 908
34. P.D. Wagner, and S. Srivastava New paradigms in translational science research in cancer biomarkers Transl Res 159 2012 343 353
35. J.L. Slocum, M. Heung, and S. Pennathur Marking renal injury: can we move beyond serum creatinine? Transl Res 159 2012 277 289
36. W. Ju, S. Smith, and M. Kretzler Genomic biomarkers for chronic kidney disease Transl Res 159 2012 290 302
37. M. Bhargava, and C.H. Wendt Biomarkers in acute lung injury Transl Res 159 2012 205 217
38. L.B. Ware Pathophysiology of acute lung injury and the acute respiratory distress syndrome Semin Respir Crit Care Med 27 2006 337 349
39. R. Vij, and I. Noth Peripheral blood biomarkers in idiopathic pulmonary fibrosis Transl Res 159 2012 218 227
40. C.B. Cooper The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function Am J Med 119 10 Suppl. 1 2006 21 31
41. S.R. Rosenberg, and R. Kahlan Biomarkers in chronic obstructive pulmonary disease Transl Res 159 2012 228 237
42. H.N. Iskandar, and M.A. Ciorba Biomarkers in inflammatory bowel disease: current practices and recent advances Transl Res 159 2012 313 325
43. T.J. Lyons, and A. Basu Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers Transl Res 159 2012 303 312
44. J.M. Ahearn, C. Liu, A.H. Kao, and S. Manzi Biomarkers for systemic lupus erythematosus Transl Res 159 2012 326 342
45. N.G. Frangogiannis The prognostic value of monocyte chemoattractant protein-1/CCL2 in acute coronary syndromes J Am Coll Cardiol 50 2007 2125 2127
46. N.G. Frangogiannis Regulation of the inflammatory response in cardiac repair Circ Res 110 2012 159 173